RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025
Rhea-AI Summary
RxSight Inc (NASDAQ: RXST), an ophthalmic medical device company focused on providing customized vision solutions for post-cataract surgery patients, has scheduled its Q1 2025 financial results announcement for May 7, 2025 after market close.
The company will host a conference call at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss the results. Investors can participate by dialing (800) 715-9871 or (646) 307-1963 with conference code 8740296. A live audio-only webcast will be available through the investor relations website, with a recording accessible afterward.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RXST gained 1.76%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the first quarter of 2025 after the market close on Wednesday, May 7, 2025. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 8740296. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
FAQ
When will RxSight (RXST) release its Q1 2025 earnings?
How can investors join RxSight's (RXST) Q1 2025 earnings call?
What time is RxSight's (RXST) Q1 2025 earnings call?
Where can I find the replay of RxSight's (RXST) Q1 2025 earnings call?
